Rheumatology Research

Updating medications and treatment strategy for systemic lupus erythematosus: A narrative review

Document Type : Original Article

Authors

1 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences

2 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

10.32592/RR.2024.9.1.1

Abstract

Systemic lupus erythematosus (SLE) is one of the most heterogeneous systemic autoimmune diseases physicians manage. Despite therapeutic advances, the morbidity of SLE has remained considerable. All hopes for the future in this regard are pinned on targeting the interferon pathways, drugs that block B-cell function or T-cell function, Janus kinase inhibitors, also known as JAK inhibitors, and approaches involving stem cells or mesenchymal cells. New treatment recommendations clarifying anti-inflammatory and immuno-modulatory drugs emphasized the treat-to-target medical strategy, which combines low disease activity and low glucocorticoid (GC) exposure. Researchers support GCs at the lowest dose. The SLE patients need to take hydroxychloroquine. Biological medicines, including belimumab and anifrolumab, are prescribed based on disease stage and severity. To proceed with personalized therapy choices, we need a deeper understanding of biological pathways and specific disease-perpetuating components. New information from ongoing therapeutic studies and real-world data will assist in further clarifying the underlying multidimensional interrelations, bringing in a new era of precision medicine in lupus erythematosus that will benefit both patients and physicians. In order to determine the most effective therapy plan for lupus nephritis, rheumatologists and nephrologists should engage in close interdisciplinary communication. This review study will examine the most recent steps to deal with and treat this disease and future plans to help SLE patients.

Keywords

Main Subjects

References

  1.  

    1. Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol 2019; 15(9):519-32. doi: 10.1038/s41584-019-0272-0.
    2. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020; 59(Suppl5):v69-v81. doi: 10.1093/rheumatology/keaa403.
    3. U Dolgin E. Lupus in crisis: as failures pile up, clinicians call for new tools. Nat Biotechnol 2019; 37(1):7-8. doi: 10.1038/nbt0119-7.
    4. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010; 69(9):1603-11. doi: 10.1136/ard.2010.135186.
    5. Garcia A, De Sanctis JB. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus. Curr Pharm Des 2016; 22(41):6306-12. doi: 10.2174/1381612822666160831103254.
    6. Rosenau BJ, Costenbader KH, Schur PH. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis. Vasc Med 2008; 13(1):25-8. doi: 10.1177/1358863x07084912
    7. O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L. et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62(3):845-54. doi: 10.1002/art.27286.
    8. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59(12):1814-20. doi: 10.1002/art.24316.
    9. Kessel A, Rosner I, Halasz K, Grushko G, Shoenfeld Y, Paran D. et al. Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum 2009; 39(1):66-70. doi: 10.1016/j.semarthrit.2008.03.003.
    10. Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, Afshari JT. et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus 2011; 20(14):1494-500. doi: 10.1177/0961203311418706.
    11. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014; 13(7):770-7. doi: 10.1016/j.autrev.2014.01.055.
    12. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012; 51(3):491-8. doi: 10.1093/rheumatology/ker368.
    13. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393(10188):2344-58. doi: 10.1016/s0140-6736(19)30546-x..
    14. Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford) 2017; 56(suppl_1):i67-i77. doi: 10.1093/rheumatology/kew399.
    15. Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F. et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 2018; 77(11):1549-57. doi: 10.1136/annrheumdis-2018-213512.
    16. Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41(6):830-9. doi: 10.1016/j.semarthrit.2011.11.002.
    17. Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016; 25(7):727-34. doi: 10.1177/0961203315627202.
    18. Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 2014; 66(4):608-16. doi: 10.1002/acr.22173.
    19. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60(2):221-5. doi: 10.1016/0002-9343(76)90431-9
    20. Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017; 13(8):799-814. doi: 10.1080/1744666x.2017.1327352.
    21. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364(9430):263-9. doi: 10.1016/s0140-6736(04)16676-2.
    22. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A. et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374(9689):525-33. doi: 10.1016/s0140-6736(09)61340-4.
    23. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73(6):958-67. doi: 10.1136/annrheumdis-2013-205139.
    24. Morand E, Merrill JT, Isenberg DA, Kao AH, Vazquez–Mateo C, Wax S. et al. OP0251 Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension. Annals of the Rheumatic Diseases 2018; 77(Suppl 2):174-75. doi: 10.1136/annrheumdis-2018-eular.2618.
    25. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S. et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2013; 65(11):1775-85. doi: 10.1002/acr.22035.
    26. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10(1 Pt 2):77-84. Journal Article.
    27. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162(1):18-26. doi: 10.7326/m14-1030
    28. Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C. et al. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis. J Am Soc Nephrol 2017; 28(12):3671-78. doi: 10.1681/asn.2017030263.
    29. Rezaie-Yazdi, Z., et al., Combination therapy with pulse cyclophosphamide plus corticosteroids improves renal outcome in patients with lupus nephritis. MJIRI, 2005. 19(2): 109-17.
    30. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F. et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012; 21(9):944-52. doi: 10.1177/0961203312442259.
    31. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019; 15(1):30-48. doi: 10.1038/s41584-018-0133-2.
    32. Hoi AY, Morand EF. Treatment Update in Systemic Lupus Erythematous. Rheum Dis Clin North Am 2021; 47(3):513-30. doi: 10.1016/j.rdc.2021.04.012.
    33. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186(8):4794-804. doi: 10.4049/jimmunol.1000702.
    34. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118(2):415-22. doi: 10.1016/j.ophtha.2010.11.017.
    35. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993; 2 Suppl 1:S13-5. Journal Article.
    36. Chakrabarti K, McCune WJ. Advances in the clinical use of hydroxychloroquine levels. Curr Opin Rheumatol 2022; 34(3):151-57. doi: 10.1097/bor.0000000000000872.
    37. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W. et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10(5):R109. doi: 10.1186/ar2506.
    38. Sifuentes Giraldo WA, García Villanueva MJ, Boteanu AL, Lois Iglesias A, Zea Mendoza AC. New targets in systemic lupus (part 2/2). Reumatol Clin 2012; 8(5):263-9. doi: 10.1016/j.reuma.2012.01.013.
    39. Blair HA, Duggan ST. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs 2018; 78(3):355-66. doi: 10.1007/s40265-018-0872-z.
    40. Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis 2015; 7(4):115-21. doi: 10.1177/1759720x15588514.
    41. Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019; 393(10188):2332-43. doi: 10.1016/s0140-6736(19)30237-5.
    42. Signorini V, Elefante E, Zucchi D, Trentin F, Bortoluzzi A, Tani C. One year in review 2020: systemic lupus erythematosus. Clin Exp Rheumatol 2020; 38(4):592-601. Journal Article.
    43. Crow MK. Mitochondrial DNA promotes autoimmunity. Science 2019; 366(6472):1445-46. doi: 10.1126/science.aaz9308.
    44. Kim J, Gupta R, Blanco LP, Yang S, Shteinfer-Kuzmine A, Wang K. et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 2019; 366(6472):1531-36. doi: 10.1126/science.aav4011.
    45. Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y. et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022; 81(7):951-61. doi: 10.1136/annrheumdis-2021-221425.
    46. Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 2023; 82(5):639-45. doi: 10.1136/ard-2022-222748.
    47. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C. et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382(3):211-21. doi: 10.1056/NEJMoa1912196.
    48. Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P. et al. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol 2018; 70(2):266-76. doi: 10.1002/art.40360.
    49. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol 2017; 69(1):122-30. doi: 10.1002/art.39809.
    50. Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 2018; 91:45-54. doi: 10.1016/j.jaut.2018.03.003.
    51. Konya C, Paz Z, Tsokos GC. The role of T cells in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2014; 26(5):493-501. doi: 10.1097/bor.0000000000000082.
    52. van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018; 392(10155):1330-39. doi: 10.1016/s0140-6736(18)32167-6..
    53. Niebel D, de Vos L, Fetter T, Brägelmann C, Wenzel J. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. Am J Clin Dermatol 2023; 24(4):521-40. doi: 10.1007/s40257-023-00774-8.
    54. Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S. et al. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. Lupus 2020; 29(14):1902-13. doi: 10.1177/0961203320966385.
    55. Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) 2021; 60(11):5397-407. doi: 10.1093/rheumatology/keab381.
    56. Tchao, N., et al., AB0432 EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN, SELECTIVELY EXPANDS REGULATORY T CELLS IN PATIENTS WITH SLE: FINAL RESULTS OF A PHASE 1B MULTIPLE ASCENDING DOSE STUDY. 2022, BMJ Publishing Group Ltd.
    57. Kong W, Deng W, Sun Y, Huang S, Zhang Z, Shi B. et al. Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis. Clin Rheumatol 2018; 37(1):43-49. doi: 10.1007/s10067-017-3717-3.
    58. Kim YY, Park KT, Jang SY, Lee KH, Byun JY, Suh KH. et al. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther 2017; 19(1):211. doi: 10.1186/s13075-017-1402-1.
    59. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S. et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000; 356(9231):701-7. doi: 10.1016/s0140-6736(00)02627-1.
    60. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R. et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13(3):168-76. doi: 10.1191/0961203304lu525oa.
    61. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J. et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. Jama 2006; 295(5):527-35. doi: 10.1001/jama.295.5.527.
    62. Hoseinzadeh A, Rezaieyazdi Z, Mahmoudi M, Tavakol Afshari J, Lavi Arab F, Esmaeili SA. et al. Dysregulated balance in Th17/Treg axis of Pristane-induced lupus mouse model, are mesenchymal stem cells therapeutic? Int Immunopharmacol 2023; 117:109699. doi: 10.1016/j.intimp.2023.109699.
    63. Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 2022; 18(3):146-57. doi: 10.1038/s41584-021-00739-3.
    64. Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu Y-JJ. et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. The Lancet Rheumatology 2019; 1(2):e103-e10. doi: https://doi.org/10.1016/S2665-9913(19)30048-7.
    65. Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L. et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726.
    66. Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu Y-JJ. et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. The Lancet Rheumatology 2019; 1(2):e103-e10. doi: https://doi.org/10.1016/S2665-9913(19)30048-7.
    67. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6):736-45. doi: 10.1136/annrheumdis-2019-215089.
    68. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67(2):195-205. doi: 10.1136/ard.2007.070367.
    69. Pisetsky DS. EULAR recommendations for disease management: guidance not guidelines. Ann Rheum Dis 2017; 76(6):935-38. doi: 10.1136/annrheumdis-2016-211005.
    70. Boumpas DT, Bertsias GK, Fanouriakis A. 2008-2018: a decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis 2018; 77(11):1547-48. doi: 10.1136/annrheumdis-2018-214014.
    71. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80(1):14-25. doi: 10.1136/annrheumdis-2020-218272.
    72. Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine. ACR Open Rheumatol 2019; 1(9):593-99. doi: 10.1002/acr2.11084.
    73. Seo MR, Chae J, Kim YM, Cha HS, Choi SJ, Oh S. et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019; 28(6):722-30. doi: 10.1177/0961203319843343.
    74. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S. et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol 2021; 73(1):121-31. doi: 10.1002/art.41466.
    75. Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020; 7(3):433-46. doi: 10.1007/s40744-020-00212-9.
    76. Kuhn A, Aberer E, Bata-Csörgő Z, Caproni M, Dreher A, Frances C. et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2017; 31(3):389-404. doi: 10.1111/jdv.14053.
    77. Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L. et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open 2019; 5(2):e000916. doi: 10.1136/rmdopen-2019-000916.
    78. Rezaieyazdi Z, Tavakoli T, Khajehdaluee M, Honarmand S. Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. Springerplus 2014; 3:638. doi: 10.1186/2193-1801-3-638.
    79. Goswami RP, Sircar G, Sit H, Ghosh A, Ghosh P. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. J Clin Rheumatol 2019; 25(1):28-35. doi: 10.1097/rhu.0000000000000760.
    80. Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L. et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol 2019; 38(3):859-67. doi: 10.1007/s10067-018-4348-z.
    81. An Y, Zhou Y, Bi L, Liu B, Wang H, Lin J. et al. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. Clin Rheumatol 2019; 38(4):1047-54. doi: 10.1007/s10067-018-4368-8.
    82. Dall'Era M, Solomons N, Federico R, Truman M. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus 2019; 28(5):591-96. doi: 10.1177/0961203319842924.
    83. Park DJ, Kang JH, Lee KE, Bae SC, Chung WT, Choe JY. et al. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study. Clin Exp Rheumatol 2019; 37(1):89-96. 

     

Rheumatology Research
Volume 9, Issue 1
January 2024
Pages 1-13
Files
Share
How to cite
Statistics